Drugs / split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00900991 | — | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00900588 | — | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00900588 ↗ |
| Modality | Vaccine | “split-virion pandemic influenza A vaccine (H5N1)” NCT00900588 ↗ |